Ten women. One infusion. A 94 percent drop in fractures over two years. It sounds like the kind of result that ends a disease, and it is also exactly the kind of result that makes careful scientists reach for the brakes. A first-in-human trial published in Cell has the osteoporosis world excited and nervous in equal measure, and both reactions are correct.
Explain Like I'm 5 · 42-second video
Narrated and captioned. Made by The Dingo Daily from this article.
A Return Address for Your Bones
Osteoporosis happens when your body loses bone faster than it can rebuild it, leaving the skeleton brittle and prone to breaking. It affects millions of people worldwide, and there is no cure. Current drugs mostly slow the damage. As ScienceAlert laid out, they don't exactly fix the underlying problem.
Stem cells have tempted researchers for years. Mesenchymal stem/stromal cells, or MSCs, are the precursors to osteoblasts, the cells that build and repair bone. You can harvest them from bone marrow and grow them in huge numbers in a lab. The catch is a big one: when you infuse them back into the bloodstream, very few end up where you actually need them.
So the Spanish researchers gave the cells a return address. They engineered the MSCs, coating them in a special sugar, to home in on bone marrow. In mice, that coating helped the cells re-enter bone and generate tissue. Now someone has tried it on actual humans.
The Numbers That Made Everyone Sit Up
The trial tracked 10 women over age 50 with advanced osteoporosis. Each received a single infusion of her own engineered cells. Across the group, fractures fell from an average of eight per year in the two years before treatment to 0.5 per year in the two years after. That is the 94 percent figure, and it is a staggering one.
Four months in, bone biopsies showed the average area occupied by bone tissue had risen by around 70 percent. Markers of bone formation stayed elevated for half a year. Two years out, participants reported 34 percent less bone pain and a 30 percent improvement in disability scores.
The authors argue the drop in fractures can't be explained by lifestyle changes or medication changes. Ajit Varki, a physician-scientist at UC San Diego who wasn't involved, called the results "quite remarkable" and told Nature the trial showed "an almost 100 percent efficacy sustained for several years and no side effects." That is about as close to gushing as a scientist gets in public.
Now Here Come the Buzzkills, and They Have a Point
Here's the thing. Ten patients is not a lot of patients. And there was no control group. Nobody got a placebo, nobody got nothing, and nobody got a different treatment to compare against. Most of the women were also taking other osteoporosis drugs.
Physician Jan Schaefer laid out the problem on LinkedIn, and it's a good one. These women were enrolled while struggling with repeated fractures, which is their worst moment. Fracture risk isn't constant. Pick a group at its absolute worst and, statistically, a lot of them will look better later on their own. It's the same reason the guy who joins a gym after a bad breakup swears the gym fixed him.
Schaefer also flagged a plumbing problem. MSCs are 20 to 30 micrometers across, bigger than a lung capillary, so on the first pass through the circulation 50 to 80 percent of them lodge in the lungs. Very few find bone marrow on their own. You can have a perfectly good cell and achieve almost nothing because it never reaches the tissue you wanted to treat.
Nobody Actually Watched the Cells Work
This is the part that should keep the headline writers honest. The trial did not track the MSCs after infusion. Researchers don't know how many reached bone, or how long they stayed once they got there. The whole premise is that the sugar coating delivers the cells to the marrow. The human data doesn't actually confirm that happened.
So the study showed that fractures fell, bone markers moved, and biopsies looked better. What it did not show is why. It is possible the engineered cells did exactly what the mouse studies suggest. It is also possible the results had little to do with the MSCs at all.
That gap between "something improved" and "our treatment caused it" is the entire reason clinical trials have control groups. Skipping that step is fine for a first look at safety. It is not fine for a victory lap.
The Conflict-of-Interest Footnote
One more detail worth a raised eyebrow. Co-author Robert Sackstein holds intellectual-property rights to the cell-engineering technology used in the trial. That doesn't make the results fake, and disclosing it is the right thing to do. But when the person with a financial stake in the method is helping publish the glowing outcome, the rest of us are allowed to ask for a second opinion.
The same team has shown that in diabetic mice, engineered MSCs can travel to the pancreas and reverse the disease. If the technique works as advertised, the implications stretch well beyond bones. That is exactly why the evidence needs to be airtight before anyone starts selling hope.
The Real Test Is Coming
The good news is that the people who ran this study seem to know all of this. Scientists at the University of Murcia in Spain are already preparing a follow-up trial in a larger group of patients with advanced osteoporosis.
This one will randomize participants into three arms: engineered MSCs from their own bone marrow, engineered MSCs from a healthy donor, or no MSC treatment at all. That last arm is the one that matters. If the untreated group keeps fracturing while the treated groups stop, we have something real. If everyone improves, we have a very expensive lesson in regression to the mean.
The Dingo Take
In 2024, osteoporosis was an incurable condition you managed with drugs that slow the damage. By the end of 2026, a ten-person study had some people talking about reversing it. Science moves fast. Hype moves faster, and it rarely waits for a control group.
Look, this might be real. A 94 percent drop in fractures with no side effects would be one of the more important results in bone medicine in decades, and the researchers did the honest thing by designing a proper randomized trial to test it. Skeptics like Schaefer aren't killjoys. They're the reason you can trust the good news when it finally arrives.
So here's the plan. Tell your grandmother there's reason for hope, then tell her not to cancel her calcium. Wait for the randomized results. If the cells really do come home to the bone, we'll be the first to say we're thrilled. Until then, ten patients and no control group is a promising rumor, not a cure.

Comments